Items Per Page 102550 Year None20222021202020192018201720162015201420132012201120102008 November 14, 2022 VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Continued progress on previously announced strategic process to maximize shareholder value TEL AVIV, Israel and NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing targeted medicines for immune-inflammatory diseases, today Read More September 1, 2022 VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency TEL AVIV, Israel and NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), a biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced that VBL received a written notification (the “Notification Letter”) from the Nasdaq Read More August 15, 2022 VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options Exploring strategic options to maximize shareholder value; engaged Chardan as financial advisor TEL AVIV, Israel and NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced Read More August 2, 2022 VBL Therapeutics Announces Workforce Reduction TEL AVIV, Israel and NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases, today announced an organizational streamlining designed to reduce operating expenses and preserve Read More July 19, 2022 VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer - Trial Did Not Meet Statistical Significance on Improvement in Primary Endpoints of Progression Free Survival (PFS) or Overall Survival (OS) - TEL AVIV, Israel and NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for Read More May 31, 2022 VBL Therapeutics to Participate in the Jefferies Healthcare Conference TEL AVIV, Israel and NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that Dror Read More May 17, 2022 VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update OVAL Phase 3 top-line data expected in 2H 2022; with positive results, VBL anticipates submitting a BLA to the FDA in 1H 2023 Conference Call and Webcast at 8:30 a.m. ET Today TEL AVIV, Israel and NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical Read More May 10, 2022 VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17 TEL AVIV, Israel and NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that Read More May 3, 2022 VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May TEL AVIV, Israel and NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that Read More April 28, 2022 VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) TEL AVIV, Israel and NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that the Read More Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 1 - 10 of 271
November 14, 2022 VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Continued progress on previously announced strategic process to maximize shareholder value TEL AVIV, Israel and NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing targeted medicines for immune-inflammatory diseases, today Read More
September 1, 2022 VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency TEL AVIV, Israel and NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), a biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced that VBL received a written notification (the “Notification Letter”) from the Nasdaq Read More
August 15, 2022 VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options Exploring strategic options to maximize shareholder value; engaged Chardan as financial advisor TEL AVIV, Israel and NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced Read More
August 2, 2022 VBL Therapeutics Announces Workforce Reduction TEL AVIV, Israel and NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases, today announced an organizational streamlining designed to reduce operating expenses and preserve Read More
July 19, 2022 VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer - Trial Did Not Meet Statistical Significance on Improvement in Primary Endpoints of Progression Free Survival (PFS) or Overall Survival (OS) - TEL AVIV, Israel and NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for Read More
May 31, 2022 VBL Therapeutics to Participate in the Jefferies Healthcare Conference TEL AVIV, Israel and NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that Dror Read More
May 17, 2022 VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update OVAL Phase 3 top-line data expected in 2H 2022; with positive results, VBL anticipates submitting a BLA to the FDA in 1H 2023 Conference Call and Webcast at 8:30 a.m. ET Today TEL AVIV, Israel and NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical Read More
May 10, 2022 VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17 TEL AVIV, Israel and NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that Read More
May 3, 2022 VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May TEL AVIV, Israel and NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that Read More
April 28, 2022 VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) TEL AVIV, Israel and NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that the Read More